Lymphatic Leakage after Pelvic Lymphadenectomy for Cervical Cancer: A Retrospective Case-Control Study

Lymphatic Leakage after Pelvic Lymphadenectomy for Cervical Cancer: A Retrospective Case-Control Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Lymphatic Leakage after Pelvic Lymphadenectomy for Cervical Cancer: A Retrospective Case-Control Study Li Chen, Liang Lin, Ling Li, Zuolian Xie, Haixin He, Cuibo Lin, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-200065/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 18 Nov, 2021 Read the published version in BMC Cancer → Version 1 posted 11 You are reading this latest preprint version Abstract Background: The study aims to evaluate the clinical features and management of postoperative lymphatic leakage (PLL) in patients with cervical cancer who received pelvic lymphadenectomy. Methods: This retrospective study screened consecutive patients with cervical cancer (stage Ia2-IIb). Results: Among 3427 cases screened, 63 patients (1.8%) were diagnosed with PLL, which manifested as persistent abdominal drainage (42/63, 66.7%), chylous ascites (12/63, 19.0%) or vaginal drainage (9/63, 14.3%). Median time from surgery to onset of PLL was 6 days (range, 4-21 days). All cases resolved in a median 10 days (range, 3-56 days) after conservative treatment; although one case experienced recurrence of vaginal drainage after 26 days, this also resolved after conservative therapy. Multivariate analysis showed that two cycles of neoadjuvant chemotherapy (odds ratio [OR], 3.283; 95% confidence interval [95%CI], 1.289-8.360; P =0.013 ), a decrease in hemoglobin level of ≥20 and <30 g/L (OR, 6.175; 95%CI, 1.033-10.919; P =0.046) or ≥30 g/L (OR, 8.467; 95%CI, 1.248-17.426; P =0.029), and postoperative albumin level ≥30 and <35 g/L (OR, 2.552; 95%CI, 1.112-5.857; P =0.027) or <30 g/L (OR, 5.517; 95%CI, 2.047-18.148; P =0.012) were associated with PLL. Conclusion: Neoadjuvant chemotherapy, postoperative anemia and postoperative hypoproteinemia are risk factors for PLL. Cancer Biology Oncology Lymphatic leakage Lymph node dissection Cervical cancer Figures Figure 1 Background Postsurgical lymphatic leakage because of trauma to the lymphatic system is a known complication of abdominal surgery [ 1 ]. Various types of postoperative lymphatic leakage have been described including lymphatic ascites [ 2 ], lymphocele [ 3 ], lymphorrhea [ 4 ], lymphatic fistula [ 5 ], chylous ascites [ 6 ], chylorrhea [ 7 ], chyloretroperitoneum [ 8 ] and chylothorax [ 9 ]. An important cause of postoperative lymphatic leakage in patients with gynecological malignancies is pelvic and paraaortic lymphadenectomy [ 10 ]. The reported incidences of postoperative lymphatic ascites and chylous ascites in patients undergoing lymph node dissection for gynecological malignancies are 2.7–4.0% [ 10 , 11 ] and 0.17–2.0% [ 12 – 14 ], respectively. In the aspect of abdominal surgery, a number of studies believe that the number of lymph node resection is closely related to the occurrence of chylous leakage [ 15 , 18 ]. NACT may be a risk factor for chylous leakage, according to a study of chyle leakage after esophagectomy [ 16 ]. In addition, various risk factors for postoperative lymphatic leakage have been described. Cirrhosis and heart failure were considered to promote the occurrence of lymphatic leakage [ 17 ]. The extent of abdominal surgery, tumor grade, number of positive lymph nodes, number of lymph nodes harvested, neoadjuvant chemotherapy (NACT) were considered as risk factors of chylous leakage in relevant studies [ 18 – 20 ]. Early postoperative oral intake is considered to be a risk factor for chylous leakage in patients after pancreaticoduodenectomy [ 21 ], but this argument is still controversial [ 15 ]. The clinical features of postsurgical lymphatic leakage include abdominal distension, leakage of clear fluid per vagina, dyspnea, pain, nausea, vomiting, prolonged postoperative ileus, malnutrition and hypoproteinemia [ 1 , 10 , 11 ]. Computed tomography (CT), ultrasonography, magnetic resonance imaging (MRI), paracentesis, lymphangiography and lymphoscintigraphy can all facilitate the diagnosis of postoperative lymphatic leakage [ 1 ]. A variety of management techniques are available, such as conservative treatment, medium-chain triglycerides, total parenteral nutrition, somatostatin, drainage and surgery [ 1 ]. Since postoperative lymphatic leakage is uncommon, data are limited regarding the incidence of and risk factors for this complication after the surgical management of cervical cancer. Therefore, the aims of this retrospective study were to review the incidence, clinical features and management of lymphatic leakage in patients treated surgically for cervical cancer at our hospital during the past decade and to identify risk factors for the occurrence of this complication. Materials And Methods Study design and study participants This retrospective case-control study included consecutive patients diagnosed with lymphatic leakage after radical hysterectomy and pelvic lymph node dissection for cervical cancer at the Department of Gynecology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital between January 2006 and August 2017. The inclusion criteria were: 1) age 25–70 years; 2) cervical cancer stage Ia2 to IIb; 3) treated using transabdominal/laparoscopic radical hysterectomy (type III) and pelvic lymph node dissection with/without bilateral salpingo-oophorectomy; and 4) a diagnosis of postoperative lymphatic leakage was made using the following criteria: i) continuous discharge of a clear, pale-yellow or chyle-like fluid from the abdominal drainage tube or vagina after surgery; ii) daily drainage volume > 200 mL; iii) drainage volume increased rapidly after feeding; iv) laboratory examinations of the drainage fluid revealed a positive chyle test, a total protein level about half that of plasma, similar electrolyte levels to plasma, and a triglycerides level > 110 mg/dL; and v) urinary fistula was excluded [ 13 , 16 ]. The exclusion criteria were: 1) paraaortic lymph node dissection was also performed during surgery; 2) other surgical procedures were carried out during the operation, such as splenectomy, intestinal resection or intestinal neoplasty; 3) a second operation was performed after the initial surgery for any reason; 4) development of a urinary fistula or intestinal fistula after surgery; and 5) serious comorbid diseases, such as systemic lupus erythematosus or Sjögren's syndrome, that required medical intervention or hormone therapy. In addition to the case group (i.e., patients diagnosed with postoperative lymphatic leakage), an equal number of patients without postoperative lymphatic leakage were enrolled as a control group. The patients in the control group were also selected from those who underwent radical hysterectomy and pelvic lymph node dissection for cervical cancer at our department. The control group of patients was matched 1:1 with the case group for age (within 5 years) and date of surgery (within 1 week); if more than one medical record met the requirements for matching, the medical record with the closest surgical time to the patient in the case group was selected. This study was approved by our hospital’s ethics committee, and the requirement for consent was waived because the analysis was retrospective. However, all patients provided informed consent for the treatments they received. Follow-up and collection of clinical data All patients were followed-up monthly for the first 6 months, every 3 months from 6 months to 2 years, every 6 months from 2 years to 5 years, and annually thereafter. All patients included in the analysis were followed-up for at least 2 years. The following data were extracted from the medical records: age; height; weight; body mass index (BMI); FIGO (International Federation of Gynecology and Obstetrics) stage; histologic type of cervical cancer; comorbidities; number of NACT treatments; neoadjuvant radiotherapy use; type of surgery (laparoscopic or open); intraoperative blood loss; number of lymph nodes resected; presence/absence of lymph node metastasis; preoperative and postoperative levels of hemoglobin (measured using a colorimetric method) and albumin (measured using the bromocresol green method) in peripheral venous blood; and whether postoperative pelvic infection occurred. The postoperative levels of hemoglobin and albumin were measured at 2 days and 5 days after surgery, and the lowest value for each parameter were used in the analysis. Resolution of lymphatic leakage after treatment was defined as a drainage volume < 150 mL/day for more than 3 days, < 10 mL of vaginal drainage, or a reduction in the triglyceride level in the drainage fluid to < 110 mL/dL. Statistical analysis The analysis was performed using SPSS 21.0 (IBM Corp., Armonk, NY, USA). All continuous measurement data were tested for normality and confirmed to have a normal distribution. Continuous data are presented as the mean ± standard deviation and were compared between groups using the t-test for independent samples. Categorical data are presented as n (%) and were compared between groups using the chi-squared test. Parameters that differed significantly ( P < 0.05) between the case group and control group in the univariate analysis were entered into a multivariate conditional logistic regression analysis (using the enter method) to identify factors independently associated with postoperative lymphatic leakage (Table 1 ). Parameters were excluded from the multivariate analysis if they exhibited collinearity with other variables. Odds ratios (ORs) and 95% confidence intervals (95%CIs) were calculated. P < 0.05 was considered significant. Table 1 Assignment of variables in the multivariate logistic regression analysis. Value Assignment in multivariate analysis Preoperative albumin (g/L) ≥ 35 < 35 and ≥ 30 < 30 1 2 3 Postoperative hemoglobin (g/L) ≥ 110 < 110 and ≥ 90 < 90 1 2 3 Postoperative albumin(g/L) ≥ 35 < 35 and ≥ 30 < 30 1 2 3 Decrease in hemoglobin (g/L) < 10 < 20 and ≥ 10 < 30 and ≥ 20 ≥ 30 1 2 3 4 Decrease in albumin (g/L) < 5 < 10 and ≥ 5 < 15 and ≥ 10 ≥ 15 1 2 3 4 Number of lymph nodes resected ༜25 1 ༜35 and ≥ 25 2 ≥ 35 3 Results Clinical characteristics of the study participants Among 3427 patients with cervical cancer treated surgically at our hospital during the study period, 63 patients (1.8%) had lymphatic leakage after the operation. The clinical characteristics of these 63 patients with postoperative lymphatic leakage (case group) are shown in Table 2 . The median time from surgery to development of lymphatic leakage was 6 days (range, 4–21 days). Postsurgical lymphatic leakage presented as persistent abdominal drainage of non-bloody fluid in 42 patients (average maximum daily drainage volume of 610 ± 127 mL), chylous ascites (confirmed by its milky color) in 12 patients, and vaginal discharge of fluid in 9 patients. Laparoscopic and open surgery were used in 24 patients (38.1%) and 39 patients (61.9%), respectively. The median number of lymph nodes resected was 32 (range, 18–62). Table 2 Clinical characteristics of the study participants. Characteristic Case group ( n = 63) Control group ( n = 63) P value Age 52.86 ± 8.56 51.59 ± 7.81 0.386 Height (cm) 157.78 ± 4.23 158.29 ± 4.17 0.499 Weight (kg) 58.25 ± 4.78 57.37 ± 5.86 0.352 Body mass index (kg/m 2 ) 23.39 ± 1.67 22.85 ± 1.74 0.078 Comorbid diabetes mellitus Yes No 19 (30.2%) 44 (69.8%) 13 (20.6%) 50 (79.4%) 0.219 FIGO Stage I II 32 (50.8%) 31 (49.2%) 31 (49.2%) 32 (50.8%) 0.859 Histologic type Squamous cell carcinoma Adenocarcinoma Other 45 (71.4%) 12 (19.0%) 6 (9.5%) 38 (60.3%) 19 (30.2%) 6 (9.5%) 0.338 Number of NACT cycles 0 1 2 26 (41.3%) 12 (19.0%) 25 (39.7%) 37 (58.7%) 13 (20.6%) 13 (20.6%) 0.021* Neoadjuvant radiotherapy Yes No 37 (58.7%) 26 (41.3%) 26 (41.3%) 37 (58.7%) 0.051 Surgical method Laparoscopy Laparotomy 24 (38.1%) 39 (61.9%) 22 (34.9%) 41 (65.1%) 0.672 Duration of surgery (h) 3.2 ± 1.0 2.9 ± 0.9 0.983 Intraoperative bleeding volume (mL) 253 ± 75 256 ± 71 0.770 Number of lymph nodes resected 37 ± 7 34 ± 8 0.008* Lymph node metastasis Yes No 6 (9.5%) 57 (90.5%) 1 (1.6%) 62 (98.4%) 0.052 Postoperative pelvic infection Yes No 22 (34.9%) 41 (65.1%) 12 (19.0%) 51 (81.0%) 0.045* Preoperative hemoglobin level (g/L) 137.08 ± 4.15 136.52 ± 5.16 0.506 Preoperative albumin level (g/L) 39.68 ± 4.15 38.10 ± 5.16 0.000* Postoperative hemoglobin level (g/L) 97.44 ± 8.44 101.40 ± 8.56 0.010* Postoperative albumin level (g/L) 30.39 ± 2.14 31.40 ± 2.83 0.025* Decrease in hemoglobin level (g/L) § 39.63 ± 8.83 35.13 ± 7.44 0.002* Decrease in albumin level (g/L) § 9.29 ± 2.15 6.70 ± 2.34 0.000* Data are presented as mean ± standard deviation or n (%). NACT: neoadjuvant chemotherapy. § Preoperative level minus postoperative level. * P < 0.05. The control group consisted of 63 patients who were matched with the case group for age and time of admission; the clinical characteristics of the control group are presented in Table 2 . There were no differences between the case and control groups in age, height, weight, BMI, prevalence of comorbid diabetes mellitus, FIGO stage, histologic type of cervical cancer, use of neoadjuvant radiotherapy, preoperative hemoglobin level, surgical method, duration of surgery, intraoperative blood loss or prevalence of lymph node metastasis (Table 2 ). However, compared with the control group, the case group had significantly greater use of NACT, higher preoperative albumin level, greater number of lymph nodes resected, higher incidence of postoperative pelvic infection, lower postoperative levels of hemoglobin and albumin, and larger decreases in hemoglobin and albumin levels from before surgery to after surgery (all P < 0.05; see Table 2 for details). Management of postoperative lymphatic leakage All cases with postsurgical lymphatic leakage resolved after conservative treatment (Fig. 1 ), which included routine placement of an indwelling drainage tube ( n = 38), administration of a low-fat and high-protein diet ( n = 59), total parenteral nutrition ( n = 46) and somatostatin ( n = 39). The median time from onset to resolution of lymphatic leakage was 10 days (range, 6–56 days). During the follow-up period, one case had a recurrence of vaginal fluid leakage 26 days after initially successful treatment; this resolved after 5 further days of conservative treatment and did not subsequently recur. Multivariate regression analysis of factors associated with postoperative lymphatic leakage Based on the results of the univariate analyses, number of lymph nodes resected, NACT use, the decrease in hemoglobin level from before surgery and postoperative albumin level were entered into the multivariate regression analysis. Preoperative and postoperative hemoglobin levels, preoperative albumin level and decrease in the level of albumin to after surgery were not entered into the multivariate analysis due to collinearity with the decrease in hemoglobin level from before surgery and postoperative albumin level. Postoperative pelvic infection was also excluded from the analysis due to collinearity with albumin level ( p = 0.031). The multivariate analysis showed that two cycles of NACT (OR, 3.283; 95%CI, 1.289–8.360; P = 0.013), a decrease in hemoglobin level of ≥ 20 and < 30 g/L (OR, 6.175; 95%CI, 1.033–10.919; P = 0.046) or ≥ 30 g/L (OR, 8.467; 95%CI, 1.248–17.426; P = 0.029), and postoperative albumin level ≥ 30 and < 35 g/L (OR, 2.552; 95%CI, 1.112–5.857; P = 0.027) or < 30 g/L (OR, 5.517; 95%CI, 2.047–18.148; P = 0.012) were significantly associated with postoperative lymphatic leakage (Table 3 ). Table 3 Multivariate analysis of factors associated with postoperative lymphatic leakage. Factor OR 95% CI P value Number of NACT cycles 0 - 1 2.679 0.876–8.197 0.084 2 3.283 1.289–8.360 0.013* Decrease in hemoglobin level (g/L) < 10 - ≥ 10 and < 20 4.973 0.810–6.542 0.083 ≥ 20 and < 30 6.175 1.033–10.919 0.046* ≥ 30 8.467 1.248–17.426 0.029* Postoperative albumin level (g/L) ≥ 35 - ≥ 30 and < 35 2.552 1.112–5.857 0.027* < 30 5.517 2.047–18.148 0.012* Number of lymph nodes resected ༜25 - ༜35 and ≥ 25 2.561 0.172–8.008 0.405 ≥ 35 3.049 0.221–12.011 0.081 NACT: neoadjuvant chemotherapy; OR: odds ratio; 95%CI: 95% confidence interval. * P < 0.05. Discussion This study found that only 63 of 3427 patients who underwent radical hysterectomy and pelvic lymph node dissection for cervical cancer were diagnosed with postoperative lymphatic leakage, corresponding to an incidence rate of 1.8%. Furthermore, the condition manifested as persistent abdominal drainage in 66.7% of cases, chylous ascites in 19.0% of cases, and vaginal drainage in 14.3% of cases. The time from surgery to onset of postoperative lymphatic leakage ranged from 4–21 days, and all cases resolved in a median 10 days (range, 3–56 days) after conservative treatment. Notably, two cycles of neoadjuvant chemotherapy, a decrease in hemoglobin level of ≥ 20 g/L after surgery and postoperative albumin level < 35 g/L were significantly associated with postoperative lymphatic leakage. Our findings show that postoperative lymphatic leakage is an uncommon complication of lymphadenectomy for cervical cancer and may be managed with conservative treatments. Since postoperative anemia and postoperative hypoproteinemia are risk factors for postoperative lymphatic leakage, attention should be made to meeting the nutritional needs of patients after surgery for cervical cancer. Lymphatic leakage is an uncommon surgical complication. Prior studies of patients who underwent lymph node dissection for gynecological malignancies have reported incidences of postoperative lymphatic leakage varying from 0.17–4.0% [ 10 – 14 ]. The incidence of postoperative lymphatic leakage in the present study was 1.8%, which is comparable to that reported previously. The occurrence of lymphatic leakage after surgery for cervical cancer likely results from damage to the lymphatic vessels. The extent of lymph node dissection is closely related to the occurrence of lymph leakage. In the present study, univariate analysis indicated that a significantly larger number of lymph nodes was dissected in the case group (patients diagnosed with postoperative lymphatic leakage) than in the control group. In agreement with our findings, other studies have also reported that a greater range of surgical dissection is associated with an increased risk of lymphatic leakage [ 15 , 17 – 19 ]. However, there was no significant difference between the case group and control group in surgical method used (laparoscopic or open), in contrast to the findings of Perez-Medina et al. [ 20 ]. The characteristics of lymphatic leakage vary according to its location and the components of its lymphatic fluid. In particular, the fluid is clear or pale-yellow in color when lymphatic leakage occurs in the pelvic cavity but is milky when lymphatic vessels of the digestive tract are damaged due to the triglyceride-rich content. An important finding of the present study was that although preoperative hemoglobin levels were similar between the case and control groups, a decrease in hemoglobin level of ≥ 20 g/L after surgery was independently associated with increased odds of lymphatic leakage. This is consistent with a previous univariate analysis that chylous ascites may be associated with the duration of surgery and intraoperative blood loss [ 21 ]. Although further research is needed to confirm our observations, we consider that the timely correction of postoperative anemia may decrease the risk of lymphatic leakage after surgery. Our analysis also found that a lower postoperative albumin level was independently associated with lymphatic leakage. Furthermore, other studies have found that lower BMI may be a risk factor for lymphatic leakage [ 22 , 23 ], implying that nutritional deficiency may enhance the risk of lymphatic leakage after an operation. We consider that the association between hypoproteinemia and postoperative lymphatic leakage may involve a decrease in the fluid pressure in the abdominal and pelvic cavities. Thus, we suggest that the provision of adequate nutrition to correct disturbances in plasma protein levels may reduce the risk of lymphatic leakage after surgery. Interestingly, the preoperative albumin level in the case group was slightly higher than that in the control group. We speculate that more attention may have been paid to perioperative nutrition (e.g., administration of protein supplements) in patients identified as having preoperative hypoproteinemia, which limited the decrease in their albumin levels after surgery. Although additional research is needed to fully characterize the relations of preoperative/postoperative albumin levels with lymphatic leakage, it is important that adequate perioperative nutrition be provided to all patients. NACT and/or neoadjuvant radiotherapy can reduce the clinical stage of a tumor and make the tumor resectable. A notable finding of this study was that the use of two cycles of NACT was associated with increased odds of lymphatic leakage, in agreement with a previous report [ 22 ]. One possible reason for this is that the patients who received NACT would likely have had more advanced cancers and thus greater tumor invasion into local tissues, resulting in surgery that was more difficult and longer in duration, which in turn caused increased intraoperative damage to lymphatic vessels. Chemotherapy can also lead to hepatic dysfunction, immune dysfunction and poor nutritional status [ 24 ], leading to anemia and hypoproteinemia, and this may increase the risk of postoperative lymphatic fistula. In the univariate analysis, postoperative pelvic infection was considered as a possible risk factor for lymphatic leakage after surgery. Postoperative pelvic infection may lead to changes in the micro-environment of the abdominal cavity, aggravating tissue edema and lowering the body protein level. However, collinearity with albumin level prevented this factor being entered into the multivariate analysis, so further research is needed to explore whether pelvic infection is related to lymphatic leakage. Lymphatic leakage is usually managed conservatively, and the vast majority of cases resolve after the use of such therapies [ 17 ]. The available conservative treatments include routine placement of an indwelling drainage tube and provision of a low-fat diet supplemented with medium-chain triglycerides [ 25 ] with or without enteral nutrition or total parenteral nutrition. In addition, somatostatin has a good effect in patients with a large amount of transudate. Treatment should be individualized and adjusted to the severity of the lymphatic leakage and its consequences [ 26 ]. Although not all patients show recovery after fasting and somatostatin treatment, the initiation of a low-fat and high-protein diet for more than ten days usually achieves a curative effect through tissue self-repair. Lymphangiography is useful for detecting lymphatic leakage occurring after lymph node dissection, and lymphatic embolization is regarded as a new option in the treatment of lymphatic leakage [ 27 , 28 ]. This study has some limitations. First, since this was a retrospective analysis, the results may be prone to selection bias and information bias. Second, the generalizability of the findings is not known because all patients were from a single institution. Third, the sample size was small, so the study may have been underpowered to detect some real differences between groups. Fourth, collinearity prevented the inclusion of some parameters in the multivariate analysis, so their possible effects on the risk of lymphatic leakage could not be evaluated. Fifth, other unknown confounding factors may have influenced the results. Multicenter, large-scale, prospective studies are needed to extend our observations. In conclusion, postoperative lymphatic leakage is a rare complication of radical hysterectomy and pelvic node resection for cervical cancer. However, cases of postoperative lymphatic leakage can be managed successfully with conservative treatments. Since postoperative anemia and postoperative hypoproteinemia are risk factors for postsurgical lymphatic leakage, attention should be paid to actively correcting anemia and meeting the nutritional needs of patients after surgery for cervical cancer. List Of Abbreviations postoperative lymphatic leakage (PLL) neoadjuvant chemotherapy (NACT) computed tomography (CT) Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of the Fujian Cancer Hospital & Fujian Medical University Cancer Hospital. All methods were performed in accordance with the relevant guidelines and regulations, and all participants provided written informed consent. Consent for publication Not applicable. Availability of data and materials Data are available upon reasonable request from corresponding author. Competing interests All authors declare that they have no competing interests. Funding None. Authors' contributions Li Chen, Liang Lin, Cuibo Lin and Jian Chen carried out the studies, participated in collecting data, and drafted the manuscript. Li Chen, and Zuolian Xie performed the statistical analysis and participated in its design. An Lin, Haixin He and Ling Li helped to draft the manuscript. All authors read and approved the final manuscript. Acknowledgements None. References Lv S, Wang Q, Zhao W, Han L, Wang Q, Batchu N, et al. A review of the postoperative lymphatic leakage. Oncotarget. 2017;8:69062-75. doi: 10.18632/oncotarget.17297 Micha JP, Mendivil AA, Cupp JS, Goldstein BH. Recurrent lymphatic ascites in a patient cured of cervical carcinoma. Gynecol Oncol Case Rep. 2012;2:105-6. doi: 10.1016/j.gynor.2012.05.004 Ghezzi F, Uccella S, Cromi A, Bogani G, Robba C, Serati M, et al. Lymphoceles, lymphorrhea, and lymphedema after laparoscopic and open endometrial cancer staging. Ann Surg Oncol. 2012;19:259-67. doi: 10.1245/s10434-011-1854-5 Sheng-Zhang L, Hong-Fei T, Zhong-Lin N, Yao-Jun Y, Tao Y, Wei Z. Treatment and prevention of lymphorrhea after radical gastrectomy of gastric cancer. J Cancer Res Clin Oncol. 2009;135:613-6. doi: 10.1007/s00432-008-0495-y Kadota H, Kakiuchi Y, Yoshida T. Management of chylous fistula after neck dissection using negative-pressure wound therapy: A preliminary report. Laryngoscope. 2012;122:997-9. doi: 10.1002/lary.23216 Shibuya Y, Asano K, Hayasaka A, Shima T, Akagi K, Ozawa N, et al. A novel therapeutic strategy for chylous ascites after gynecological cancer surgery: a continuous low-pressure drainage system. Arch Gynecol Obstet. 2013;287:1005-8. doi: 10.1007/s00404-012-2666-y Matsutani T, Hirakata A, Nomura T, Hagiwara N, Matsuda A, Yoshida H, et al. Transabdominal approach for chylorrhea after esophagectomy by using fluorescence navigation with indocyanine green. Case Rep Surg. 2014;2014:464017. doi: 10.1155/2014/464017 Negoro H, Oka H, Kawakita M. Two cases of chyloretroperitoneum following retroperitoneoscopic nephroureterectomy. Int J Urol. 2006;13:487-9. doi: 10.1111/j.1442-2042.2006.01427.x Liu CY, Hsu PK, Huang CS, Sun YH, Wu YC, Hsu WH. Chylothorax complicating video-assisted thoracoscopic surgery for non-small cell lung cancer. World J Surg. 2014;38:2875-81. doi: 10.1007/s00268-014-2699-4 Frey MK, Ward NM, Caputo TA, Taylor J, Worley MJ, Jr., Slomovitz BM. Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies. Gynecol Oncol. 2012;125:48-53. doi: 10.1016/j.ygyno.2011.11.012 Krishnan CS, Grant PT, Robertson G, Hacker NF. Lymphatic ascites following lymphadenectomy for gynecological malignancy. Int J Gynecol Cancer. 2001;11:392-6. doi: 10.1046/j.1525-1438.2001.01050.x Han D, Wu X, Li J, Ke G. Postoperative chylous ascites in patients with gynecologic malignancies. Int J Gynecol Cancer. 2012;22:186-90. doi: 10.1097/IGC.0b013e318233f24b Zhao Y, Hu W, Hou X, Zhou Q. Chylous ascites after laparoscopic lymph node dissection in gynecologic malignancies. J Minim Invasive Gynecol. 2014;21:90-6. doi: 10.1016/j.jmig.2013.07.005 Tulunay G, Ureyen I, Turan T, Karalok A, Kavak D, Ozgul N, et al. Chylous ascites: analysis of 24 patients. Gynecol Oncol. 2012;127:191-7. doi: 10.1016/j.ygyno.2012.06.023 Chen Z, Zhang Z, Lin B, Feng W, Meng F, Shi X. Relationship Between Early Oral Intake Post Pancreaticoduodenectomy and Chyle Leakage: A Retrospective Cohort Study. J Invest Surg. 20191-9. doi: 10.1080/08941939.2019.1663378 Roberts JR, Walters GK, Zenilman ME, Jones CE. Groin lymphorrhea complicating revascularization involving the femoral vessels. Am J Surg. 1993;165:341-4. doi: 10.1016/s0002-9610(05)80839-6 Weniger M, D'Haese JG, Angele MK, Kleespies A, Werner J, Hartwig W. Treatment options for chylous ascites after major abdominal surgery: a systematic review. Am J Surg. 2016;211:206-13. doi: 10.1016/j.amjsurg.2015.04.012 Qureshi SS, Rent EG, Bhagat M, Dsouza P, Kembhavi S, Vora T, et al. Chyle leak following surgery for abdominal neuroblastoma. J Pediatr Surg. 2016;51:1557-60. doi: 10.1016/j.jpedsurg.2015.11.002 Ji W, Wang J, Song B, Zheng K, Ma H, Nadaf A, et al. Cause analysis and therapeutic methods of chylous leakage after pancreaticoduodenectomy. Saudi Med J. 2014;35:1396-9. Perez-Medina T, Pereira A, San-Frutos L, García-Espantaleón M, Chiverto Y, Engels V, et al. Lymphatic ascites after retroperitoneal lymphadenectomy in gynecologic cancer. Surg Oncol. 2015;24:300-4. doi: 10.1016/j.suronc.2015.06.003 Baek SJ, Kim SH, Kwak JM, Kim J. Incidence and risk factors of chylous ascites after colorectal cancer surgery. Am J Surg. 2013;206:555-9. doi: 10.1016/j.amjsurg.2013.01.033 Weijs TJ, Ruurda JP, Broekhuizen ME, Bracco Gartner TCL, van Hillegersberg R. Outcome of a Step-Up Treatment Strategy for Chyle Leakage After Esophagectomy. Ann Thorac Surg. 2017;104:477-84. doi: 10.1016/j.athoracsur.2017.01.117 Miao L, Zhang Y, Hu H, Ma L, Shun Y, Xiang J, et al. Incidence and management of chylothorax after esophagectomy. Thorac Cancer. 2015;6:354-8. doi: 10.1111/1759-7714.12240 Aredes MA, Garcez MR, Chaves GV. Influence of chemoradiotherapy on nutritional status, functional capacity, quality of life and toxicity of treatment for patients with cervical cancer. Nutr Diet. 2018;75:263-70. doi: 10.1111/1747-0080.12414 Pan W, Cai SY, Luo HL, Ouyang SR, Zhang WD, Wei ZR, et al. The application of nutrition support in conservative treatment of chylous ascites after abdominal surgery. Ther Clin Risk Manag. 2016;12:607-12. doi: 10.2147/tcrm.s100266 Leibovitch I, Mor Y, Golomb J, Ramon J. The diagnosis and management of postoperative chylous ascites. J Urol. 2002;167:449-57. doi: 10.1097/00005392-200202000-00003 Lee EW, Shin JH, Ko HK, Park J, Kim SH, Sung KB. Lymphangiography to treat postoperative lymphatic leakage: a technical review. Korean J Radiol. 2014;15:724-32. doi: 10.3348/kjr.2014.15.6.724 Baek Y, Won JH, Kong TW, Paek J, Chang SJ, Ryu HS, et al. Lymphatic Leak Occurring After Surgical Lymph Node Dissection: A Preliminary Study Assessing the Feasibility and Outcome of Lymphatic Embolization. Cardiovasc Intervent Radiol. 2016;39:1728-35. doi: 10.1007/s00270-016-1435-x Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 18 Nov, 2021 Read the published version in BMC Cancer → Version 1 posted Editorial decision: Major revision 14 Apr, 2021 Reviews received at journal 04 Apr, 2021 Reviewers agreed at journal 02 Apr, 2021 Reviews received at journal 25 Feb, 2021 Reviewers agreed at journal 24 Feb, 2021 Reviewers agreed at journal 23 Feb, 2021 Reviewers invited by journal 22 Feb, 2021 Editor assigned by journal 22 Feb, 2021 Editor invited by journal 22 Feb, 2021 Submission checks completed at journal 22 Feb, 2021 First submitted to journal 03 Feb, 2021 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-200065","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":13098251,"identity":"f5a92aae-1237-42fa-825f-90a084ec0edb","order_by":0,"name":"Li Chen","email":"","orcid":"","institution":"Fujian Cancer Hospital \u0026 Fujian Medical University Cancer Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Li","middleName":"","lastName":"Chen","suffix":""},{"id":13098252,"identity":"2a9c182e-3658-44a7-84a0-cb4fd6af2d9b","order_by":1,"name":"Liang Lin","email":"","orcid":"","institution":"Fujian Cancer Hospital \u0026 Fujian Medical University Cancer Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Liang","middleName":"","lastName":"Lin","suffix":""},{"id":13098253,"identity":"dc77b5c9-207c-41c4-a209-3d2e0b310ea9","order_by":2,"name":"Ling Li","email":"","orcid":"","institution":"Fujian Cancer Hospital \u0026 Fujian Medical University Cancer Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ling","middleName":"","lastName":"Li","suffix":""},{"id":13098254,"identity":"ecc6bad0-8027-4e91-9e9a-20b1ebbffef5","order_by":3,"name":"Zuolian Xie","email":"","orcid":"","institution":"Fujian Cancer Hospital \u0026 Fujian Medical University Cancer Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Zuolian","middleName":"","lastName":"Xie","suffix":""},{"id":13098255,"identity":"026747f3-8dc0-44d9-a15c-a821953a214c","order_by":4,"name":"Haixin He","email":"","orcid":"","institution":"Fujian Cancer Hospital \u0026 Fujian Medical University Cancer Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Haixin","middleName":"","lastName":"He","suffix":""},{"id":13098256,"identity":"77376a91-30ad-4a49-ad5a-47898f9fcb4c","order_by":5,"name":"Cuibo Lin","email":"","orcid":"","institution":"Fujian Cancer Hospital \u0026 Fujian Medical University Cancer Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Cuibo","middleName":"","lastName":"Lin","suffix":""},{"id":13098257,"identity":"623fd756-6c3c-4b1f-95c2-2a44f7d87857","order_by":6,"name":"Jian Chen","email":"","orcid":"","institution":"Fujian Cancer Hospital \u0026 Fujian Medical University Cancer Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Jian","middleName":"","lastName":"Chen","suffix":""},{"id":13098258,"identity":"8169304d-715b-4a43-badc-7b75eae1d250","order_by":7,"name":"An Lin","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7UlEQVRIie3RMQrCMBSA4Rce2CWxa4rQXiFSECfvIl1d3BxEKgFdvIAo3sGlOFoCuniADi7eoOIkOJhWER1sHB3yDw8yfISXANhsfxnGWxj4CA4tThzAMRKiySFEwAfhgD8QIJMQngTMxF2Mx6q/Ek4gWXq6btojVwLJz73vhB/TWM0TgUTWo5AdOOcK0JsnFddk3Vix5IaItNUgE72LghqyChKUZCmwpol31SQwEVGSWCDVhDNNhIk0C0J3AjnSsNjFWysiK3fxs0hd6FBEwXTW1C82cv29TPNz1frPonLqP3pNY503YrPZbLbP7oNORuaAi8zgAAAAAElFTkSuQmCC","orcid":"","institution":"Fujian Cancer Hospital \u0026 Fujian Medical University Cancer Hospital","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"An","middleName":"","lastName":"Lin","suffix":""}],"badges":[],"createdAt":"2021-02-03 09:51:35","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-200065/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-200065/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s12885-021-08984-1","type":"published","date":"2021-11-18T18:49:24+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":6258354,"identity":"b7fca061-3c5a-435a-8aa4-74dc356663e9","added_by":"auto","created_at":"2021-02-23 15:22:19","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":254972,"visible":true,"origin":"","legend":"Flowchart of enrolment and analysis process","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-200065/v1/c6374f47fdbf1f68c89f8c11.jpg"},{"id":15687977,"identity":"250f35a9-ada2-41e6-8d29-dac54f88108d","added_by":"auto","created_at":"2021-11-18 18:49:27","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":424841,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-200065/v1/fd77d638-383f-4e93-a875-db2c12a1ebbb.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Lymphatic Leakage after Pelvic Lymphadenectomy for Cervical Cancer: A Retrospective Case-Control Study","fulltext":[{"header":"Background","content":"\u003cp\u003ePostsurgical lymphatic leakage because of trauma to the lymphatic system is a known complication of abdominal surgery [\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e]. Various types of postoperative lymphatic leakage have been described including lymphatic ascites [\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e], lymphocele [\u003cspan class=\"CitationRef\"\u003e3\u003c/span\u003e], lymphorrhea [\u003cspan class=\"CitationRef\"\u003e4\u003c/span\u003e], lymphatic fistula [\u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e], chylous ascites [\u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e], chylorrhea [\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e], chyloretroperitoneum [\u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e] and chylothorax [\u003cspan class=\"CitationRef\"\u003e9\u003c/span\u003e]. An important cause of postoperative lymphatic leakage in patients with gynecological malignancies is pelvic and paraaortic lymphadenectomy [\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e]. The reported incidences of postoperative lymphatic ascites and chylous ascites in patients undergoing lymph node dissection for gynecological malignancies are 2.7\u0026ndash;4.0% [\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e] and 0.17\u0026ndash;2.0% [\u003cspan class=\"CitationRef\"\u003e12\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e14\u003c/span\u003e], respectively. In the aspect of abdominal surgery, a number of studies believe that the number of lymph node resection is closely related to the occurrence of chylous leakage [\u003cspan class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e]. NACT may be a risk factor for chylous leakage, according to a study of chyle leakage after esophagectomy [\u003cspan class=\"CitationRef\"\u003e16\u003c/span\u003e]. In addition, various risk factors for postoperative lymphatic leakage have been described. Cirrhosis and heart failure were considered to promote the occurrence of lymphatic leakage [\u003cspan class=\"CitationRef\"\u003e17\u003c/span\u003e]. The extent of abdominal surgery, tumor grade, number of positive lymph nodes, number of lymph nodes harvested, neoadjuvant chemotherapy (NACT) were considered as risk factors of chylous leakage in relevant studies [\u003cspan class=\"CitationRef\"\u003e18\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e]. Early postoperative oral intake is considered to be a risk factor for chylous leakage in patients after pancreaticoduodenectomy [\u003cspan class=\"CitationRef\"\u003e21\u003c/span\u003e], but this argument is still controversial [\u003cspan class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e\n\u003cp\u003eThe clinical features of postsurgical lymphatic leakage include abdominal distension, leakage of clear fluid per vagina, dyspnea, pain, nausea, vomiting, prolonged postoperative ileus, malnutrition and hypoproteinemia [\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e]. Computed tomography (CT), ultrasonography, magnetic resonance imaging (MRI), paracentesis, lymphangiography and lymphoscintigraphy can all facilitate the diagnosis of postoperative lymphatic leakage [\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e]. A variety of management techniques are available, such as conservative treatment, medium-chain triglycerides, total parenteral nutrition, somatostatin, drainage and surgery [\u003cspan class=\"CitationRef\"\u003e1\u003c/span\u003e].\u003c/p\u003e\n\u003cp\u003eSince postoperative lymphatic leakage is uncommon, data are limited regarding the incidence of and risk factors for this complication after the surgical management of cervical cancer. Therefore, the aims of this retrospective study were to review the incidence, clinical features and management of lymphatic leakage in patients treated surgically for cervical cancer at our hospital during the past decade and to identify risk factors for the occurrence of this complication.\u003c/p\u003e"},{"header":"Materials And Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\n\u003cp\u003e\u003cstrong\u003eStudy design and study participants\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis retrospective case-control study included consecutive patients diagnosed with lymphatic leakage after radical hysterectomy and pelvic lymph node dissection for cervical cancer at the Department of Gynecology, Fujian Cancer Hospital \u0026amp; Fujian Medical University Cancer Hospital between January 2006 and August 2017. The inclusion criteria were: 1) age 25\u0026ndash;70 years; 2) cervical cancer stage Ia2 to IIb; 3) treated using transabdominal/laparoscopic radical hysterectomy (type III) and pelvic lymph node dissection with/without bilateral salpingo-oophorectomy; and 4) a diagnosis of postoperative lymphatic leakage was made using the following criteria: i) continuous discharge of a clear, pale-yellow or chyle-like fluid from the abdominal drainage tube or vagina after surgery; ii) daily drainage volume\u0026thinsp;\u0026gt;\u0026thinsp;200 mL; iii) drainage volume increased rapidly after feeding; iv) laboratory examinations of the drainage fluid revealed a positive chyle test, a total protein level about half that of plasma, similar electrolyte levels to plasma, and a triglycerides level\u0026thinsp;\u0026gt;\u0026thinsp;110 mg/dL; and v) urinary fistula was excluded [\u003cspan class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e16\u003c/span\u003e]. The exclusion criteria were: 1) paraaortic lymph node dissection was also performed during surgery; 2) other surgical procedures were carried out during the operation, such as splenectomy, intestinal resection or intestinal neoplasty; 3) a second operation was performed after the initial surgery for any reason; 4) development of a urinary fistula or intestinal fistula after surgery; and 5) serious comorbid diseases, such as systemic lupus erythematosus or Sj\u0026ouml;gren's syndrome, that required medical intervention or hormone therapy. In addition to the case group (i.e., patients diagnosed with postoperative lymphatic leakage), an equal number of patients without postoperative lymphatic leakage were enrolled as a control group. The patients in the control group were also selected from those who underwent radical hysterectomy and pelvic lymph node dissection for cervical cancer at our department. The control group of patients was matched 1:1 with the case group for age (within 5 years) and date of surgery (within 1 week); if more than one medical record met the requirements for matching, the medical record with the closest surgical time to the patient in the case group was selected.\u003c/p\u003e\n\u003cp\u003eThis study was approved by our hospital\u0026rsquo;s ethics committee, and the requirement for consent was waived because the analysis was retrospective. However, all patients provided informed consent for the treatments they received.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFollow-up and collection of clinical data\u003c/strong\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e\n\u003cp\u003eAll patients were followed-up monthly for the first 6 months, every 3 months from 6 months to 2 years, every 6 months from 2 years to 5 years, and annually thereafter. All patients included in the analysis were followed-up for at least 2 years. The following data were extracted from the medical records: age; height; weight; body mass index (BMI); FIGO (International Federation of Gynecology and Obstetrics) stage; histologic type of cervical cancer; comorbidities; number of NACT treatments; neoadjuvant radiotherapy use; type of surgery (laparoscopic or open); intraoperative blood loss; number of lymph nodes resected; presence/absence of lymph node metastasis; preoperative and postoperative levels of hemoglobin (measured using a colorimetric method) and albumin (measured using the bromocresol green method) in peripheral venous blood; and whether postoperative pelvic infection occurred. The postoperative levels of hemoglobin and albumin were measured at 2 days and 5 days after surgery, and the lowest value for each parameter were used in the analysis. Resolution of lymphatic leakage after treatment was defined as a drainage volume\u0026thinsp;\u0026lt;\u0026thinsp;150 mL/day for more than 3 days, \u0026lt; 10 mL of vaginal drainage, or a reduction in the triglyceride level in the drainage fluid to \u0026lt;\u0026thinsp;110 mL/dL.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\n\u003cp\u003eThe analysis was performed using SPSS 21.0 (IBM Corp., Armonk, NY, USA). All continuous measurement data were tested for normality and confirmed to have a normal distribution. Continuous data are presented as the mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation and were compared between groups using the t-test for independent samples. Categorical data are presented as \u003cem\u003en\u003c/em\u003e (%) and were compared between groups using the chi-squared test. Parameters that differed significantly (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05) between the case group and control group in the univariate analysis were entered into a multivariate conditional logistic regression analysis (using the enter method) to identify factors independently associated with postoperative lymphatic leakage (Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e). Parameters were excluded from the multivariate analysis if they exhibited collinearity with other variables. Odds ratios (ORs) and 95% confidence intervals (95%CIs) were calculated. \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered significant.\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab1\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eAssignment of variables in the multivariate logistic regression analysis.\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\u0026nbsp;\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eValue\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eAssignment in multivariate analysis\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePreoperative albumin (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;35\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;35 and \u0026ge;\u0026thinsp;30\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;30\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePostoperative hemoglobin (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;110\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;110 and \u0026ge;\u0026thinsp;90\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;90\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePostoperative albumin(g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;35\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;35 and \u0026ge;\u0026thinsp;30\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;30\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDecrease in hemoglobin (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;10\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;20 and \u0026ge;\u0026thinsp;10\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;30 and \u0026ge;\u0026thinsp;20\u003c/p\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;30\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003cp\u003e4\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDecrease in albumin (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;5\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;10 and \u0026ge;\u0026thinsp;5\u003c/p\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;15 and \u0026ge;\u0026thinsp;10\u003c/p\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003cp\u003e4\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNumber of lymph nodes resected\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e༜25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e༜35 and \u0026ge;\u0026thinsp;25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;35\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\n\u003cp\u003e\u003cstrong\u003eClinical characteristics of the study participants\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAmong 3427 patients with cervical cancer treated surgically at our hospital during the study period, 63 patients (1.8%) had lymphatic leakage after the operation. The clinical characteristics of these 63 patients with postoperative lymphatic leakage (case group) are shown in Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e. The median time from surgery to development of lymphatic leakage was 6 days (range, 4\u0026ndash;21 days). Postsurgical lymphatic leakage presented as persistent abdominal drainage of non-bloody fluid in 42 patients (average maximum daily drainage volume of 610\u0026thinsp;\u0026plusmn;\u0026thinsp;127 mL), chylous ascites (confirmed by its milky color) in 12 patients, and vaginal discharge of fluid in 9 patients. Laparoscopic and open surgery were used in 24 patients (38.1%) and 39 patients (61.9%), respectively. The median number of lymph nodes resected was 32 (range, 18\u0026ndash;62).\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab2\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eClinical characteristics of the study participants.\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eCharacteristic\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eCase group\u003c/p\u003e\n\u003cp\u003e(\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;63)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eControl group\u003c/p\u003e\n\u003cp\u003e(\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;63)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAge\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e52.86\u0026thinsp;\u0026plusmn;\u0026thinsp;8.56\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e51.59\u0026thinsp;\u0026plusmn;\u0026thinsp;7.81\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.386\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHeight (cm)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e157.78\u0026thinsp;\u0026plusmn;\u0026thinsp;4.23\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e158.29\u0026thinsp;\u0026plusmn;\u0026thinsp;4.17\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.499\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eWeight (kg)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e58.25\u0026thinsp;\u0026plusmn;\u0026thinsp;4.78\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e57.37\u0026thinsp;\u0026plusmn;\u0026thinsp;5.86\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.352\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eBody mass index (kg/m\u003csup\u003e2\u003c/sup\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e23.39\u0026thinsp;\u0026plusmn;\u0026thinsp;1.67\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e22.85\u0026thinsp;\u0026plusmn;\u0026thinsp;1.74\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.078\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eComorbid diabetes mellitus\u003c/p\u003e\n\u003cp\u003eYes\u003c/p\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e19 (30.2%)\u003c/p\u003e\n\u003cp\u003e44 (69.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e13 (20.6%)\u003c/p\u003e\n\u003cp\u003e50 (79.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.219\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFIGO Stage\u003c/p\u003e\n\u003cp\u003eI\u003c/p\u003e\n\u003cp\u003eII\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e32 (50.8%)\u003c/p\u003e\n\u003cp\u003e31 (49.2%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e31 (49.2%)\u003c/p\u003e\n\u003cp\u003e32 (50.8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.859\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHistologic type\u003c/p\u003e\n\u003cp\u003eSquamous cell carcinoma\u003c/p\u003e\n\u003cp\u003eAdenocarcinoma\u003c/p\u003e\n\u003cp\u003eOther\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e45 (71.4%)\u003c/p\u003e\n\u003cp\u003e12 (19.0%)\u003c/p\u003e\n\u003cp\u003e6 (9.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e38 (60.3%)\u003c/p\u003e\n\u003cp\u003e19 (30.2%)\u003c/p\u003e\n\u003cp\u003e6 (9.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.338\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNumber of NACT cycles\u003c/p\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e26 (41.3%)\u003c/p\u003e\n\u003cp\u003e12 (19.0%)\u003c/p\u003e\n\u003cp\u003e25 (39.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e37 (58.7%)\u003c/p\u003e\n\u003cp\u003e13 (20.6%)\u003c/p\u003e\n\u003cp\u003e13 (20.6%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.021*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNeoadjuvant radiotherapy\u003c/p\u003e\n\u003cp\u003eYes\u003c/p\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e37 (58.7%)\u003c/p\u003e\n\u003cp\u003e26 (41.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e26 (41.3%)\u003c/p\u003e\n\u003cp\u003e37 (58.7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.051\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSurgical method\u003c/p\u003e\n\u003cp\u003eLaparoscopy\u003c/p\u003e\n\u003cp\u003eLaparotomy\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e24 (38.1%)\u003c/p\u003e\n\u003cp\u003e39 (61.9%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e22 (34.9%)\u003c/p\u003e\n\u003cp\u003e41 (65.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.672\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDuration of surgery (h)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e3.2\u0026thinsp;\u0026plusmn;\u0026thinsp;1.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e2.9\u0026thinsp;\u0026plusmn;\u0026thinsp;0.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.983\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eIntraoperative bleeding volume (mL)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e253\u0026thinsp;\u0026plusmn;\u0026thinsp;75\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e256\u0026thinsp;\u0026plusmn;\u0026thinsp;71\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.770\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNumber of lymph nodes resected\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e37\u0026thinsp;\u0026plusmn;\u0026thinsp;7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e34\u0026thinsp;\u0026plusmn;\u0026thinsp;8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.008*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLymph node metastasis\u003c/p\u003e\n\u003cp\u003eYes\u003c/p\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6 (9.5%)\u003c/p\u003e\n\u003cp\u003e57 (90.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1 (1.6%)\u003c/p\u003e\n\u003cp\u003e62 (98.4%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.052\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePostoperative pelvic infection\u003c/p\u003e\n\u003cp\u003eYes\u003c/p\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e22 (34.9%)\u003c/p\u003e\n\u003cp\u003e41 (65.1%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e12 (19.0%)\u003c/p\u003e\n\u003cp\u003e51 (81.0%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.045*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePreoperative hemoglobin level (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e137.08\u0026thinsp;\u0026plusmn;\u0026thinsp;4.15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e136.52\u0026thinsp;\u0026plusmn;\u0026thinsp;5.16\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.506\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePreoperative albumin level (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e39.68\u0026thinsp;\u0026plusmn;\u0026thinsp;4.15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e38.10\u0026thinsp;\u0026plusmn;\u0026thinsp;5.16\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.000*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePostoperative hemoglobin level (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e97.44\u0026thinsp;\u0026plusmn;\u0026thinsp;8.44\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e101.40\u0026thinsp;\u0026plusmn;\u0026thinsp;8.56\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.010*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePostoperative albumin level (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e30.39\u0026thinsp;\u0026plusmn;\u0026thinsp;2.14\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e31.40\u0026thinsp;\u0026plusmn;\u0026thinsp;2.83\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.025*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDecrease in hemoglobin level (g/L)\u003csup\u003e\u0026sect;\u003c/sup\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e39.63\u0026thinsp;\u0026plusmn;\u0026thinsp;8.83\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e35.13\u0026thinsp;\u0026plusmn;\u0026thinsp;7.44\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.002*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDecrease in albumin level (g/L)\u003csup\u003e\u0026sect;\u003c/sup\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e9.29\u0026thinsp;\u0026plusmn;\u0026thinsp;2.15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\"\u0026plusmn;\"\u003e\n\u003cp\u003e6.70\u0026thinsp;\u0026plusmn;\u0026thinsp;2.34\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.000*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003ctfoot\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\"\u003eData are presented as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation or \u003cem\u003en\u003c/em\u003e (%). NACT: neoadjuvant chemotherapy. \u003csup\u003e\u0026sect;\u003c/sup\u003e Preoperative level minus postoperative level. * \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tfoot\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe control group consisted of 63 patients who were matched with the case group for age and time of admission; the clinical characteristics of the control group are presented in Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e. There were no differences between the case and control groups in age, height, weight, BMI, prevalence of comorbid diabetes mellitus, FIGO stage, histologic type of cervical cancer, use of neoadjuvant radiotherapy, preoperative hemoglobin level, surgical method, duration of surgery, intraoperative blood loss or prevalence of lymph node metastasis (Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e). However, compared with the control group, the case group had significantly greater use of NACT, higher preoperative albumin level, greater number of lymph nodes resected, higher incidence of postoperative pelvic infection, lower postoperative levels of hemoglobin and albumin, and larger decreases in hemoglobin and albumin levels from before surgery to after surgery (all \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05; see Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003e for details).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eManagement of postoperative lymphatic leakage\u003c/strong\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\n\u003cp\u003eAll cases with postsurgical lymphatic leakage resolved after conservative treatment (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e), which included routine placement of an indwelling drainage tube (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;38), administration of a low-fat and high-protein diet (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;59), total parenteral nutrition (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;46) and somatostatin (\u003cem\u003en\u003c/em\u003e\u0026thinsp;=\u0026thinsp;39). The median time from onset to resolution of lymphatic leakage was 10 days (range, 6\u0026ndash;56 days). During the follow-up period, one case had a recurrence of vaginal fluid leakage 26 days after initially successful treatment; this resolved after 5 further days of conservative treatment and did not subsequently recur.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMultivariate regression analysis of factors associated with postoperative lymphatic leakage\u003c/strong\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e\n\u003cp\u003eBased on the results of the univariate analyses, number of lymph nodes resected, NACT use, the decrease in hemoglobin level from before surgery and postoperative albumin level were entered into the multivariate regression analysis. Preoperative and postoperative hemoglobin levels, preoperative albumin level and decrease in the level of albumin to after surgery were not entered into the multivariate analysis due to collinearity with the decrease in hemoglobin level from before surgery and postoperative albumin level. Postoperative pelvic infection was also excluded from the analysis due to collinearity with albumin level (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.031). The multivariate analysis showed that two cycles of NACT (OR, 3.283; 95%CI, 1.289\u0026ndash;8.360; \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.013), a decrease in hemoglobin level of \u0026ge;\u0026thinsp;20 and \u0026lt;\u0026thinsp;30 g/L (OR, 6.175; 95%CI, 1.033\u0026ndash;10.919; \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.046) or \u0026ge;\u0026thinsp;30 g/L (OR, 8.467; 95%CI, 1.248\u0026ndash;17.426; \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.029), and postoperative albumin level\u0026thinsp;\u0026ge;\u0026thinsp;30 and \u0026lt;\u0026thinsp;35 g/L (OR, 2.552; 95%CI, 1.112\u0026ndash;5.857; \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.027) or \u0026lt;\u0026thinsp;30 g/L (OR, 5.517; 95%CI, 2.047\u0026ndash;18.148; \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.012) were significantly associated with postoperative lymphatic leakage (Table\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab3\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eMultivariate analysis of factors associated with postoperative lymphatic leakage.\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eFactor\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eOR\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e95% CI\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNumber of NACT cycles\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.679\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.876\u0026ndash;8.197\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.084\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3.283\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1.289\u0026ndash;8.360\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.013*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDecrease in hemoglobin level (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;10 and \u0026lt;\u0026thinsp;20\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4.973\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.810\u0026ndash;6.542\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.083\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;20 and \u0026lt;\u0026thinsp;30\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6.175\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1.033\u0026ndash;10.919\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.046*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;30\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e8.467\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1.248\u0026ndash;17.426\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.029*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePostoperative albumin level (g/L)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;35\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;30 and \u0026lt;\u0026thinsp;35\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.552\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e1.112\u0026ndash;5.857\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.027*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026lt;\u0026thinsp;30\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5.517\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e2.047\u0026ndash;18.148\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.012*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNumber of lymph nodes resected\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e༜25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e༜35 and \u0026ge;\u0026thinsp;25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.561\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.172\u0026ndash;8.008\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.405\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026ge;\u0026thinsp;35\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3.049\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.221\u0026ndash;12.011\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e0.081\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003ctfoot\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"5\"\u003eNACT: neoadjuvant chemotherapy; OR: odds ratio; 95%CI: 95% confidence interval. *\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tfoot\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis study found that only 63 of 3427 patients who underwent radical hysterectomy and pelvic lymph node dissection for cervical cancer were diagnosed with postoperative lymphatic leakage, corresponding to an incidence rate of 1.8%. Furthermore, the condition manifested as persistent abdominal drainage in 66.7% of cases, chylous ascites in 19.0% of cases, and vaginal drainage in 14.3% of cases. The time from surgery to onset of postoperative lymphatic leakage ranged from 4\u0026ndash;21 days, and all cases resolved in a median 10 days (range, 3\u0026ndash;56 days) after conservative treatment. Notably, two cycles of neoadjuvant chemotherapy, a decrease in hemoglobin level of \u0026ge;\u0026thinsp;20 g/L after surgery and postoperative albumin level\u0026thinsp;\u0026lt;\u0026thinsp;35 g/L were significantly associated with postoperative lymphatic leakage. Our findings show that postoperative lymphatic leakage is an uncommon complication of lymphadenectomy for cervical cancer and may be managed with conservative treatments. Since postoperative anemia and postoperative hypoproteinemia are risk factors for postoperative lymphatic leakage, attention should be made to meeting the nutritional needs of patients after surgery for cervical cancer.\u003c/p\u003e\n\u003cp\u003eLymphatic leakage is an uncommon surgical complication. Prior studies of patients who underwent lymph node dissection for gynecological malignancies have reported incidences of postoperative lymphatic leakage varying from 0.17\u0026ndash;4.0% [\u003cspan class=\"CitationRef\"\u003e10\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e14\u003c/span\u003e]. The incidence of postoperative lymphatic leakage in the present study was 1.8%, which is comparable to that reported previously.\u003c/p\u003e\n\u003cp\u003eThe occurrence of lymphatic leakage after surgery for cervical cancer likely results from damage to the lymphatic vessels. The extent of lymph node dissection is closely related to the occurrence of lymph leakage. In the present study, univariate analysis indicated that a significantly larger number of lymph nodes was dissected in the case group (patients diagnosed with postoperative lymphatic leakage) than in the control group. In agreement with our findings, other studies have also reported that a greater range of surgical dissection is associated with an increased risk of lymphatic leakage [\u003cspan class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e]. However, there was no significant difference between the case group and control group in surgical method used (laparoscopic or open), in contrast to the findings of Perez-Medina et al. [\u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e]. The characteristics of lymphatic leakage vary according to its location and the components of its lymphatic fluid. In particular, the fluid is clear or pale-yellow in color when lymphatic leakage occurs in the pelvic cavity but is milky when lymphatic vessels of the digestive tract are damaged due to the triglyceride-rich content.\u003c/p\u003e\n\u003cp\u003eAn important finding of the present study was that although preoperative hemoglobin levels were similar between the case and control groups, a decrease in hemoglobin level of \u0026ge;\u0026thinsp;20 g/L after surgery was independently associated with increased odds of lymphatic leakage. This is consistent with a previous univariate analysis that chylous ascites may be associated with the duration of surgery and intraoperative blood loss [\u003cspan class=\"CitationRef\"\u003e21\u003c/span\u003e]. Although further research is needed to confirm our observations, we consider that the timely correction of postoperative anemia may decrease the risk of lymphatic leakage after surgery.\u003c/p\u003e\n\u003cp\u003eOur analysis also found that a lower postoperative albumin level was independently associated with lymphatic leakage. Furthermore, other studies have found that lower BMI may be a risk factor for lymphatic leakage [\u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e23\u003c/span\u003e], implying that nutritional deficiency may enhance the risk of lymphatic leakage after an operation. We consider that the association between hypoproteinemia and postoperative lymphatic leakage may involve a decrease in the fluid pressure in the abdominal and pelvic cavities. Thus, we suggest that the provision of adequate nutrition to correct disturbances in plasma protein levels may reduce the risk of lymphatic leakage after surgery. Interestingly, the preoperative albumin level in the case group was slightly higher than that in the control group. We speculate that more attention may have been paid to perioperative nutrition (e.g., administration of protein supplements) in patients identified as having preoperative hypoproteinemia, which limited the decrease in their albumin levels after surgery. Although additional research is needed to fully characterize the relations of preoperative/postoperative albumin levels with lymphatic leakage, it is important that adequate perioperative nutrition be provided to all patients.\u003c/p\u003e\n\u003cp\u003eNACT and/or neoadjuvant radiotherapy can reduce the clinical stage of a tumor and make the tumor resectable. A notable finding of this study was that the use of two cycles of NACT was associated with increased odds of lymphatic leakage, in agreement with a previous report [\u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e]. One possible reason for this is that the patients who received NACT would likely have had more advanced cancers and thus greater tumor invasion into local tissues, resulting in surgery that was more difficult and longer in duration, which in turn caused increased intraoperative damage to lymphatic vessels. Chemotherapy can also lead to hepatic dysfunction, immune dysfunction and poor nutritional status [\u003cspan class=\"CitationRef\"\u003e24\u003c/span\u003e], leading to anemia and hypoproteinemia, and this may increase the risk of postoperative lymphatic fistula.\u003c/p\u003e\n\u003cp\u003eIn the univariate analysis, postoperative pelvic infection was considered as a possible risk factor for lymphatic leakage after surgery. Postoperative pelvic infection may lead to changes in the micro-environment of the abdominal cavity, aggravating tissue edema and lowering the body protein level. However, collinearity with albumin level prevented this factor being entered into the multivariate analysis, so further research is needed to explore whether pelvic infection is related to lymphatic leakage.\u003c/p\u003e\n\u003cp\u003eLymphatic leakage is usually managed conservatively, and the vast majority of cases resolve after the use of such therapies [\u003cspan class=\"CitationRef\"\u003e17\u003c/span\u003e]. The available conservative treatments include routine placement of an indwelling drainage tube and provision of a low-fat diet supplemented with medium-chain triglycerides [\u003cspan class=\"CitationRef\"\u003e25\u003c/span\u003e] with or without enteral nutrition or total parenteral nutrition. In addition, somatostatin has a good effect in patients with a large amount of transudate. Treatment should be individualized and adjusted to the severity of the lymphatic leakage and its consequences [\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e]. Although not all patients show recovery after fasting and somatostatin treatment, the initiation of a low-fat and high-protein diet for more than ten days usually achieves a curative effect through tissue self-repair. Lymphangiography is useful for detecting lymphatic leakage occurring after lymph node dissection, and lymphatic embolization is regarded as a new option in the treatment of lymphatic leakage [\u003cspan class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e28\u003c/span\u003e].\u003c/p\u003e\n\u003cp\u003eThis study has some limitations. First, since this was a retrospective analysis, the results may be prone to selection bias and information bias. Second, the generalizability of the findings is not known because all patients were from a single institution. Third, the sample size was small, so the study may have been underpowered to detect some real differences between groups. Fourth, collinearity prevented the inclusion of some parameters in the multivariate analysis, so their possible effects on the risk of lymphatic leakage could not be evaluated. Fifth, other unknown confounding factors may have influenced the results. Multicenter, large-scale, prospective studies are needed to extend our observations.\u003c/p\u003e\n\u003cp\u003eIn conclusion, postoperative lymphatic leakage is a rare complication of radical hysterectomy and pelvic node resection for cervical cancer. However, cases of postoperative lymphatic leakage can be managed successfully with conservative treatments. Since postoperative anemia and postoperative hypoproteinemia are risk factors for postsurgical lymphatic leakage, attention should be paid to actively correcting anemia and meeting the nutritional needs of patients after surgery for cervical cancer.\u003c/p\u003e\n"},{"header":"List Of Abbreviations","content":"\u003cp\u003epostoperative lymphatic leakage (PLL)\u003c/p\u003e\n\u003cp\u003eneoadjuvant chemotherapy (NACT)\u003c/p\u003e\n\u003cp\u003ecomputed tomography (CT)\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was approved by the Ethics Committee of the Fujian Cancer Hospital \u0026amp; Fujian Medical University Cancer Hospital. All methods were performed in accordance with the relevant guidelines and regulations, and all participants provided written informed consent.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eData are available upon reasonable request from corresponding author.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNone.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors' contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eLi Chen, Liang Lin, Cuibo Lin and Jian Chen carried out the studies, participated in collecting data, and drafted the manuscript. Li Chen, and Zuolian Xie performed the statistical analysis and participated in its design. An Lin, Haixin He and Ling Li helped to draft the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNone.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eLv S, Wang Q, Zhao W, Han L, Wang Q, Batchu N, et al. A review of the postoperative lymphatic leakage. Oncotarget. 2017;8:69062-75. doi: 10.18632/oncotarget.17297\u003c/li\u003e\n\u003cli\u003eMicha JP, Mendivil AA, Cupp JS, Goldstein BH. Recurrent lymphatic ascites in a patient cured of cervical carcinoma. Gynecol Oncol Case Rep. 2012;2:105-6. doi: 10.1016/j.gynor.2012.05.004\u003c/li\u003e\n\u003cli\u003eGhezzi F, Uccella S, Cromi A, Bogani G, Robba C, Serati M, et al. Lymphoceles, lymphorrhea, and lymphedema after laparoscopic and open endometrial cancer staging. Ann Surg Oncol. 2012;19:259-67. doi: 10.1245/s10434-011-1854-5\u003c/li\u003e\n\u003cli\u003eSheng-Zhang L, Hong-Fei T, Zhong-Lin N, Yao-Jun Y, Tao Y, Wei Z. Treatment and prevention of lymphorrhea after radical gastrectomy of gastric cancer. J Cancer Res Clin Oncol. 2009;135:613-6. doi: 10.1007/s00432-008-0495-y\u003c/li\u003e\n\u003cli\u003eKadota H, Kakiuchi Y, Yoshida T. Management of chylous fistula after neck dissection using negative-pressure wound therapy: A preliminary report. Laryngoscope. 2012;122:997-9. doi: 10.1002/lary.23216\u003c/li\u003e\n\u003cli\u003eShibuya Y, Asano K, Hayasaka A, Shima T, Akagi K, Ozawa N, et al. A novel therapeutic strategy for chylous ascites after gynecological cancer surgery: a continuous low-pressure drainage system. Arch Gynecol Obstet. 2013;287:1005-8. doi: 10.1007/s00404-012-2666-y\u003c/li\u003e\n\u003cli\u003eMatsutani T, Hirakata A, Nomura T, Hagiwara N, Matsuda A, Yoshida H, et al. Transabdominal approach for chylorrhea after esophagectomy by using fluorescence navigation with indocyanine green. Case Rep Surg. 2014;2014:464017. doi: 10.1155/2014/464017\u003c/li\u003e\n\u003cli\u003eNegoro H, Oka H, Kawakita M. Two cases of chyloretroperitoneum following retroperitoneoscopic nephroureterectomy. Int J Urol. 2006;13:487-9. doi: 10.1111/j.1442-2042.2006.01427.x\u003c/li\u003e\n\u003cli\u003eLiu CY, Hsu PK, Huang CS, Sun YH, Wu YC, Hsu WH. Chylothorax complicating video-assisted thoracoscopic surgery for non-small cell lung cancer. World J Surg. 2014;38:2875-81. doi: 10.1007/s00268-014-2699-4\u003c/li\u003e\n\u003cli\u003eFrey MK, Ward NM, Caputo TA, Taylor J, Worley MJ, Jr., Slomovitz BM. Lymphatic ascites following pelvic and paraaortic lymphadenectomy procedures for gynecologic malignancies. Gynecol Oncol. 2012;125:48-53. doi: 10.1016/j.ygyno.2011.11.012\u003c/li\u003e\n\u003cli\u003eKrishnan CS, Grant PT, Robertson G, Hacker NF. Lymphatic ascites following lymphadenectomy for gynecological malignancy. Int J Gynecol Cancer. 2001;11:392-6. doi: 10.1046/j.1525-1438.2001.01050.x\u003c/li\u003e\n\u003cli\u003eHan D, Wu X, Li J, Ke G. Postoperative chylous ascites in patients with gynecologic malignancies. Int J Gynecol Cancer. 2012;22:186-90. doi: 10.1097/IGC.0b013e318233f24b\u003c/li\u003e\n\u003cli\u003eZhao Y, Hu W, Hou X, Zhou Q. Chylous ascites after laparoscopic lymph node dissection in gynecologic malignancies. J Minim Invasive Gynecol. 2014;21:90-6. doi: 10.1016/j.jmig.2013.07.005\u003c/li\u003e\n\u003cli\u003eTulunay G, Ureyen I, Turan T, Karalok A, Kavak D, Ozgul N, et al. Chylous ascites: analysis of 24 patients. Gynecol Oncol. 2012;127:191-7. doi: 10.1016/j.ygyno.2012.06.023\u003c/li\u003e\n\u003cli\u003eChen Z, Zhang Z, Lin B, Feng W, Meng F, Shi X. Relationship Between Early Oral Intake Post Pancreaticoduodenectomy and Chyle Leakage: A Retrospective Cohort Study. J Invest Surg. 20191-9. doi: 10.1080/08941939.2019.1663378\u003c/li\u003e\n\u003cli\u003eRoberts JR, Walters GK, Zenilman ME, Jones CE. Groin lymphorrhea complicating revascularization involving the femoral vessels. Am J Surg. 1993;165:341-4. doi: 10.1016/s0002-9610(05)80839-6\u003c/li\u003e\n\u003cli\u003eWeniger M, D'Haese JG, Angele MK, Kleespies A, Werner J, Hartwig W. Treatment options for chylous ascites after major abdominal surgery: a systematic review. Am J Surg. 2016;211:206-13. doi: 10.1016/j.amjsurg.2015.04.012\u003c/li\u003e\n\u003cli\u003eQureshi SS, Rent EG, Bhagat M, Dsouza P, Kembhavi S, Vora T, et al. Chyle leak following surgery for abdominal neuroblastoma. J Pediatr Surg. 2016;51:1557-60. doi: 10.1016/j.jpedsurg.2015.11.002\u003c/li\u003e\n\u003cli\u003eJi W, Wang J, Song B, Zheng K, Ma H, Nadaf A, et al. Cause analysis and therapeutic methods of chylous leakage after pancreaticoduodenectomy. Saudi Med J. 2014;35:1396-9.\u003c/li\u003e\n\u003cli\u003ePerez-Medina T, Pereira A, San-Frutos L, Garc\u0026iacute;a-Espantale\u0026oacute;n M, Chiverto Y, Engels V, et al. Lymphatic ascites after retroperitoneal lymphadenectomy in gynecologic cancer. Surg Oncol. 2015;24:300-4. doi: 10.1016/j.suronc.2015.06.003\u003c/li\u003e\n\u003cli\u003eBaek SJ, Kim SH, Kwak JM, Kim J. Incidence and risk factors of chylous ascites after colorectal cancer surgery. Am J Surg. 2013;206:555-9. doi: 10.1016/j.amjsurg.2013.01.033\u003c/li\u003e\n\u003cli\u003eWeijs TJ, Ruurda JP, Broekhuizen ME, Bracco Gartner TCL, van Hillegersberg R. Outcome of a Step-Up Treatment Strategy for Chyle Leakage After Esophagectomy. Ann Thorac Surg. 2017;104:477-84. doi: 10.1016/j.athoracsur.2017.01.117\u003c/li\u003e\n\u003cli\u003eMiao L, Zhang Y, Hu H, Ma L, Shun Y, Xiang J, et al. Incidence and management of chylothorax after esophagectomy. Thorac Cancer. 2015;6:354-8. doi: 10.1111/1759-7714.12240\u003c/li\u003e\n\u003cli\u003eAredes MA, Garcez MR, Chaves GV. Influence of chemoradiotherapy on nutritional status, functional capacity, quality of life and toxicity of treatment for patients with cervical cancer. Nutr Diet. 2018;75:263-70. doi: 10.1111/1747-0080.12414\u003c/li\u003e\n\u003cli\u003ePan W, Cai SY, Luo HL, Ouyang SR, Zhang WD, Wei ZR, et al. The application of nutrition support in conservative treatment of chylous ascites after abdominal surgery. Ther Clin Risk Manag. 2016;12:607-12. doi: 10.2147/tcrm.s100266\u003c/li\u003e\n\u003cli\u003eLeibovitch I, Mor Y, Golomb J, Ramon J. The diagnosis and management of postoperative chylous ascites. J Urol. 2002;167:449-57. doi: 10.1097/00005392-200202000-00003\u003c/li\u003e\n\u003cli\u003eLee EW, Shin JH, Ko HK, Park J, Kim SH, Sung KB. Lymphangiography to treat postoperative lymphatic leakage: a technical review. Korean J Radiol. 2014;15:724-32. doi: 10.3348/kjr.2014.15.6.724\u003c/li\u003e\n\u003cli\u003eBaek Y, Won JH, Kong TW, Paek J, Chang SJ, Ryu HS, et al. Lymphatic Leak Occurring After Surgical Lymph Node Dissection: A Preliminary Study Assessing the Feasibility and Outcome of Lymphatic Embolization. Cardiovasc Intervent Radiol. 2016;39:1728-35. doi: 10.1007/s00270-016-1435-x\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Lymphatic leakage, Lymph node dissection, Cervical cancer","lastPublishedDoi":"10.21203/rs.3.rs-200065/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-200065/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground: \u003c/strong\u003eThe study aims to evaluate the clinical features and management of postoperative lymphatic leakage (PLL) in patients with cervical cancer who received pelvic lymphadenectomy. \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMethods: \u003c/strong\u003eThis retrospective study screened consecutive patients with cervical cancer (stage Ia2-IIb). \u003c/p\u003e\u003cp\u003e\u003cstrong\u003eResults: \u003c/strong\u003eAmong 3427 cases screened, 63 patients (1.8%) were diagnosed with PLL, which manifested as persistent abdominal drainage (42/63, 66.7%), chylous ascites (12/63, 19.0%) or vaginal drainage (9/63, 14.3%). Median time from surgery to onset of PLL was 6 days (range, 4-21 days). All cases resolved in a median 10 days (range, 3-56 days) after conservative treatment; although one case experienced recurrence of vaginal drainage after 26 days, this also resolved after conservative therapy. Multivariate analysis showed that two cycles of neoadjuvant chemotherapy (odds ratio [OR], 3.283; 95% confidence interval [95%CI], 1.289-8.360; \u003cem\u003eP\u003c/em\u003e=0.013 ), a decrease in hemoglobin level of ≥20 and \u0026lt;30 g/L (OR, 6.175; 95%CI, 1.033-10.919; \u003cem\u003eP\u003c/em\u003e=0.046) or ≥30 g/L (OR, 8.467; 95%CI, 1.248-17.426; \u003cem\u003eP\u003c/em\u003e=0.029), and postoperative albumin level ≥30 and \u0026lt;35 g/L (OR, 2.552; 95%CI, 1.112-5.857; \u003cem\u003eP\u003c/em\u003e=0.027) or \u0026lt;30 g/L (OR, 5.517; 95%CI, 2.047-18.148; \u003cem\u003eP\u003c/em\u003e=0.012) were associated with PLL.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConclusion: \u003c/strong\u003eNeoadjuvant chemotherapy, postoperative anemia and postoperative hypoproteinemia are risk factors for PLL.\u0026nbsp;\u003c/p\u003e","manuscriptTitle":"Lymphatic Leakage after Pelvic Lymphadenectomy for Cervical Cancer: A Retrospective Case-Control Study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2021-02-23 15:22:12","doi":"10.21203/rs.3.rs-200065/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Major revision","date":"2021-04-14T11:17:17+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2021-04-04T11:02:55+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"ce60c765-7404-403d-a069-cc176d9b2c66","date":"2021-04-03T00:00:59+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2021-02-25T06:33:33+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"aa96ce4f-beda-4cea-9a09-957cd57c6c1c","date":"2021-02-24T11:03:15+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"360af4a8-e98b-4534-9d69-8d7201323baf","date":"2021-02-24T01:41:52+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2021-02-22T17:36:56+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2021-02-22T17:33:40+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2021-02-22T12:28:00+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2021-02-22T11:47:07+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Cancer","date":"2021-02-03T09:12:30+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-cancer","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"bcan","sideBox":"Learn more about [BMC Cancer](http://bmccancer.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/bcan/default.aspx","title":"BMC Cancer","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"41579258-c1a3-47b0-9f66-71970c77135d","owner":[],"postedDate":"February 23rd, 2021","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":2581815,"name":"Cancer Biology"},{"id":2581816,"name":"Oncology"}],"tags":[],"updatedAt":"2021-11-18T18:49:24+00:00","versionOfRecord":{"articleIdentity":"rs-200065","link":"https://doi.org/10.1186/s12885-021-08984-1","journal":{"identity":"bmc-cancer","isVorOnly":false,"title":"BMC Cancer"},"publishedOn":"2021-11-18 18:49:24","publishedOnDateReadable":"November 18th, 2021"},"versionCreatedAt":"2021-02-23 15:22:12","video":"","vorDoi":"10.1186/s12885-021-08984-1","vorDoiUrl":"https://doi.org/10.1186/s12885-021-08984-1","workflowStages":[]},"version":"v1","identity":"rs-200065","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-200065","identity":"rs-200065","version":["v1"]},"buildId":"ehx78VzkSd0WSzXnipQa-","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}